Palantir and MicroStrategy Are Joining the Nasdaq 100. Which Stocks Are Getting the Boot.
Barron’s wrote Friday that Palantir and MicroStrategy led the list of potential adds to the Nasdaq 100. Palantir shifted to the Nasdaq from the NYSE in November to be eligible for inclusion in the Nasdaq 100 at the reconstitution.
Following news of RSV lower respiratory tract infections in infants immunized with Moderna’s investigational RNA vaccines, ...
The Cambridge drugmaker received approval on Thursday night from the city's Board of Zoning Appeal to display its name on a ...
Two days after the FDA revealed that it had halted enrollment in trials of respiratory syncytial virus (RSV) vaccines that ...
Norovirus vaccines face significant hurdles, with virtually no success from past efforts from HilleVax and Vaxxart. But ...
Moderna stock remains under pressure with analysts projecting steep losses in the fourth quarter. Is MRNA stock a sell in ...
Shares of Moderna Inc. MRNA slipped 2.31% to $41.83 Friday, on what proved to be an all-around mixed trading session for the ...
Analysts issued an Underperform rating for shares while reluanching coverage of large-cap U.S. pharma and biotech names.
In the chaotic early days of the pandemic, Wall Street scrambled to place bets on the companies that looked the most likely to thrive the uncharted waters that were rising all around us. The early ...
Shares of Moderna Inc. MRNA sank 0.09% to $42.82 Thursday, on what proved to be an all-around dismal trading session for the ...
The advisory committee, which met at the FDA’s request Thursday, did not reach a conclusion about the cause of a safety ...
On Tuesday, Moderna Inc (MRNA) stock saw a decline, ending the day at $41.51 which represents a decrease of $-4.14 or -9.07% from the prior close of $45.65. The stock opened at $45.36 and touched a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback